ACRIN 6678 Test/Retest Discussion

Drs. Gatsonis and Siegel joined the call to answer statistical questions and help the group to understand how the ACRIN 6678 test-retest results relate to the QIBA FDG-PET Technical Committee’s Profile Claim language.

- The ACRIN group is examining SUVMax with a 12% coefficient of variation, and a ± 33% range of repeatability
  - Aiming for a balance between scientific precision and clinical usefulness
  - Current data is based on 34 participants

- The study is very similar to one completed by Dr. Velasquez.
  - Her paper was recommended as an excellent reference for the group.

Comments regarding the ACRIN 6678 Draft Interim Report

The group reviewed and discussed areas of particular interest or concern including:

- Asymmetry of repeatability coefficients
- Similarity of SUVmax and SUV peak test-retest reproducibility
- Coefficient of Variation (COV) used in ACRIN 6678

Follow up items

- Dr. Gatsonis to send cov information to Dr. Kinahan for distribution to the group.
- Technical Committee to adjust claim using Dr. Gatsonis’ numbers
- Dr. Kinahan will send the updated version of the claim to Dr. Gatsonis for review
- RSNA Staff to send latest version of the QIBA FDG-PET Profile to Dr. Campbell for review
- RSNA Staff to arrange t-con including Drs. Lodge and Yap to address remaining items that require their expertise

Next steps:

- Approach to addressing the Public Comment phase needs further discussion, along with resolving the ACRIN 6678 test-retest results in relation to the claim.

Next call:

- Post - ACRIN 6678 Discussion of claim and remaining action items, Friday, August 31st, at 9 am CT.